دورية أكاديمية
Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis
| العنوان: | Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis |
|---|---|
| المؤلفون: | Lleixà, Cinta, Caballero Ávila, Marta, Pascual Goñi, Elba, Martín Aguilar, Lorena, Vidal, Nuria, Tejada, Clara, Valdés Hevia, Eduardo, Zárate, Elisa, Vesperinas, Ana, Collet, Roger, Franco Leyva, Teresa, Martínez Martínez, Laura, Moga, Esther, Cortés Vicente, Elena, Rojas García, Ricard, Gómez Anson, Beatriz, Gil, Anna, González Mingot, Cristina, Brieva, Luis, Martínez Yélamos, Sergio, Querol, Luis |
| المصدر: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2023 |
| المجموعة: | Dipòsit Digital de la Universitat de Barcelona |
| مصطلحات موضوعية: | Esclerosi múltiple, Antígens, Multiple sclerosis, Antigens |
| الوصف: | Lleixa and Caballero-avila et al. report that antibodies targeting the flotillin-1/2 complex are present in a subgroup of patients with multiple sclerosis. Further studies are needed to understand the clinical and pathological relevance of anti-flotillin-1/2 autoantibodies in multiple sclerosis. Multiple sclerosis is a tissue-specific autoimmune disease of the central nervous system in which the antigen(s) remains elusive. Antibodies targeting the flotillin-1/2 complex have been described in 1-2% of the patients in a recent study. Other candidate antigens as anoctamin-2 or neurofascin-155 have been previously described in multiple sclerosis patients, although their clinical relevance remains uncertain. Our study aims to analyse the frequency and clinical relevance of antibodies against neurofascin-155, anoctamin-2 and flotillin-1/2 complex in multiple sclerosis. Serum (n = 252) and CSF (n = 50) samples from 282 multiple sclerosis patients were included in the study. The control group was composed of 260 serum samples (71 healthy donors and 189 with other neuroinflammatory disorders). Anti-flotillin-1/2, anti-anoctamin-2 and anti-neurofascin-155 antibodies were tested by cell-based assays using transfected cells. We identified six multiple sclerosis patients with antibodies against the flotillin-1/2 complex (2.1%) and one multiple sclerosis patient with antibodies against anoctamin-2 (0.35%). All multiple sclerosis patients were negative for anti-neurofascin-155 antibodies. Three of the anti-flotillin-1/2 positive patients showed anti-flotillin-1/2 positivity in other serum samples extracted at different moments of their disease. Immunoglobulin G subclasses of anti-flotillin-1/2 antibodies were predominantly one and three. We confirm that antibodies targeting the flotillin-1/2 complex are present in a subgroup of patients with multiple sclerosis. Further studies are needed to understand the clinical and pathological relevance of anti-flotillin-1/2 autoantibodies in multiple sclerosis. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | 10 p.; application/pdf |
| اللغة: | English |
| تدمد: | 2632-1297 |
| العلاقة: | Reproducció del document publicat a: https://doi.org/10.1093/braincomms/fcad109Test; Brain Communications, 2023, vol. 5, num. 2; https://doi.org/10.1093/braincomms/fcad109Test; http://hdl.handle.net/2445/198662Test |
| الإتاحة: | https://doi.org/10.1093/braincomms/fcad109Test http://hdl.handle.net/2445/198662Test |
| حقوق: | cc by (c) Lleixà, Cinta et al, 2022 ; http://creativecommons.org/licenses/by/3.0/esTest/ ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.8A2E2441 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 26321297 |
|---|